GLP-1 medications are one of the most talked-about topics in health media, and one of the most distorted. A viral before-and-after, a scary headline, or a confident TikTok travels a lot faster than a 68-week clinical trial. Some of what you'll hear is flatly wrong. Some of it is true but stripped of the context that makes sense of it. A few claims are still unresolved, and careful experts disagree about them.
This guide sorts the most common claims into three buckets (Myth, Mostly true, and It's complicated) and shows the evidence behind each verdict. The aim is to help you read the next headline with a clearer eye, whatever you decide about these drugs.
"It's the easy way out. Real weight loss takes willpower"
Verdict: Myth.
This is the most common framing, and it misunderstands what obesity is. The body defends its weight through biology: hormones regulate appetite, satiety, and energy expenditure, and resolve alone doesn't override them. GLP-1 (and GIP) receptor agonists amplify the body's own satiety signaling. They blunt appetite, slow gastric emptying, and quiet the constant "food noise" many people describe. That's a physiological change.
Willpower alone doesn't produce these results. In the STEP 1 trial, adults with obesity lost on average about 15% of body weight over 68 weeks on semaglutide, against roughly 2.4% on placebo, and both groups got the same lifestyle counseling (Wilding et al., NEJM, 2021, DOI (external link)). The difference came from the medication, since the counseling was identical.
Calling it "cheating" is like calling insulin cheating. The medication treats a biological driver, and the person still does the daily work.
"You'll gain all the weight back the second you stop"
Verdict: Mostly true, and it tells you something useful.
This gets repeated as a takedown, but it's largely accurate. When semaglutide was stopped after the STEP 1 trial, participants regained about two-thirds of the weight they'd lost within a year, and much of the metabolic improvement reversed with it (Wilding et al., Diabetes, Obesity and Metabolism, 2022, DOI (external link)). Weight tends to return when treatment ends.
The takedown version leaves out that this is how chronic conditions behave. Blood pressure rises again when you stop a blood-pressure pill, and nobody concludes the pill "didn't work." Obesity is increasingly treated as a chronic, relapsing condition, so for many people the medication is a long-term management tool, not a 12-week reset. Regain shows the underlying biology is still there. Whether to stay on, taper, or stop is a real conversation to have with your prescriber.
"'Ozempic face' proves the drug prematurely ages you"
Verdict: It's complicated.
"Ozempic face", meaning hollowing or sagging in the cheeks and under the eyes, is real. There's no evidence the drug is toxic to skin. Most of it is the face doing what the rest of the body does during large, fast weight loss: losing fat. Facial fat pads shrink, and skin that stretched over more volume can look looser. The same thing happens after large weight loss from surgery or diet, and the medication's speed and size of loss make the change more noticeable than a slow diet would.
The drug may still add something. In a 2026 survey of 1,226 people on weight-management treatment, people taking only a GLP-1 medication reported more facial volume loss than people who lost a similar share of weight on other treatments (38% vs 19% at 10–20% weight loss). The authors couldn't tell whether the drug itself or the speed of loss explained the gap (Rao et al., Dermatology and Therapy, 2026, DOI (external link)).
So the headline version is wrong about the cause: this is mainly volume loss from losing weight, not premature aging. But GLP-1 users do report more of it than people losing weight other ways, and nobody yet knows why.
"They're just a vanity shortcut, not real medicine"
Verdict: Myth.
GLP-1 medications are FDA-approved to treat obesity as a disease, and the health effects go well past the number on the scale. In the SELECT trial, which enrolled 17,604 people with cardiovascular disease and overweight or obesity but without diabetes, semaglutide reduced the risk of cardiovascular death, heart attack, or stroke by 20% compared with placebo over roughly three years (Lincoff et al., NEJM, 2023, DOI (external link)). Fewer heart attacks and strokes is a medical outcome.
These drugs are also studied and used for type 2 diabetes, sleep apnea, and chronic kidney disease, among other conditions. In the SURMOUNT-OSA trials, tirzepatide cut breathing interruptions during sleep by about 20–24 more events per hour than placebo in adults with obesity and moderate-to-severe sleep apnea (Malhotra et al., NEJM, 2024, DOI (external link)). In the FLOW trial, semaglutide lowered the risk of major kidney events by 24% in people with type 2 diabetes and chronic kidney disease (Perkovic et al., NEJM, 2024, DOI (external link)).
Whatever you think about the culture around them, the medicine has hard outcomes behind it.
"GLP-1s cause thyroid cancer"
Verdict: It's complicated, and unresolved.
This isn't a clean myth, and it isn't settled fact. Most GLP-1 drugs carry a boxed warning for thyroid C-cell tumors because rodents given the drugs developed them. Rodent thyroids respond differently than human thyroids, and it has never been confirmed that the same thing happens in people. Human data conflict. A large French national study found a modestly increased risk of thyroid cancer, including medullary thyroid cancer, after 1–3 years of use (Bezin et al., Diabetes Care, 2023, DOI (external link)). A Scandinavian cohort study of more than 145,000 GLP-1 users, followed for an average of 3.9 years, found no increased risk (hazard ratio 0.93) (Pasternak et al., BMJ, 2024, DOI (external link)).
Because of the uncertainty, the GLP-1 medications that carry the boxed warning (nearly all of them) are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, a genetic syndrome. For everyone else the absolute risk appears low, but "we don't fully know yet" is the accurate answer. It's a good reason to share your family history with your prescriber, and not a reason to panic.
"They cause suicidal thoughts"
Verdict: Myth, as far as the evidence shows.
Reports of suicidal ideation prompted formal reviews by European and U.S. regulators. When researchers looked at large real-world patient records covering more than 240,000 people with overweight or obesity, semaglutide was associated with a lower risk of suicidal ideation than other weight or diabetes medications (Wang et al., Nature Medicine, 2024, DOI (external link)). European and U.S. regulatory reviews likewise found no evidence of a causal link. In January 2026 the FDA asked for the suicidal behavior and ideation warning to be removed from Saxenda, Wegovy, and Zepbound labeling after its analysis of 91 trials with 107,910 participants found no increased risk.
Mood still matters on these drugs, and you shouldn't ignore your mental health. Tell your care team about any mood changes. The specific claim that these drugs cause suicidal thoughts just isn't supported by the data we have.
"You lose mostly muscle, and it wastes your body"
Verdict: It's complicated. A real concern, and a manageable one.
Any substantial weight loss, whether from diet, surgery, or medication, costs some lean mass along with fat. A 2026 meta-analysis of 20 randomized trials found lean mass made up roughly 25–39% of the weight lost on incretin drugs, about the same share as with lifestyle-driven weight loss (26%) (Eisa & Barood, Diabetes, Obesity and Metabolism, 2026, DOI (external link)). So it isn't unique to GLP-1s, but because these drugs can drive fast, large losses, protecting muscle matters.
You can do something about it. Eating enough protein (guidance often lands around 1.2–1.6 g/kg of body weight per day, spread across meals) helps preserve lean mass and satiety during weight loss (Leidy et al., American Journal of Clinical Nutrition, 2015, DOI (external link)), and resistance training tells the body to keep the muscle it has. In the same meta-analysis, lifestyle programs that added resistance training had the smallest lean share, 17.5%. That's why nutrition and strength work belong in any GLP-1 plan.
"Slow stomach emptying makes food ferment and rot in your stomach"
Verdict: Myth, as far as the evidence shows.
Food does sit longer in a slowed stomach, and the bloating and burping that come with it are real. But we found no study showing fermentation or bacterial growth in the stomach of GLP-1 users. Stomach acid normally kills many microbes that arrive with food (Dicksved et al., Journal of Medical Microbiology, 2009, DOI (external link)), and the slowing is modest on average and fades over weeks with the long-acting drugs (Jalleh et al., Journal of Clinical Endocrinology & Metabolism, 2024, DOI (external link)). The Dicksved study looked at people with reduced stomach acid, not GLP-1 users, so it supports the general principle only.
A separate, small-intestine problem called SIBO was diagnosed somewhat more often in GLP-1 users in one retrospective study of people with type 2 diabetes (0.177 vs 0.083 per 1,000 patient-years in the first year, hazard ratio 2.14, 95% CI 1.13 to 4.07). The absolute numbers were very small and the study can't prove cause (Sun et al., Diagnostics, 2025, DOI (external link)). Persistent bloating, gas, or diarrhea is worth raising with your prescriber. Our full guide covers how much GLP-1s slow the stomach, how long it lasts, and how it's measured.
"Cheaper compounded or online versions are the same drug for less"
Verdict: Myth, and a risky one.
Not everything sold online as "semaglutide" or "tirzepatide" is what it claims to be. The FDA has warned (external link) about counterfeit and illegally sold products, dosing errors, and unapproved "research" or salt forms of these drugs. Price alone doesn't tell you what's in the vial.
Some people have legitimate reasons to use compounded medication, and some legitimate pharmacies make it. "It's cheaper, so it's the same" skips the fact that source and safety vary enormously. Before buying from an unfamiliar seller, read our companion guide on pharmacy sources for GLP-1 medications.
How to respond to the next GLP-1 headline
A few habits catch most health misinformation:
- Anecdote vs. evidence. One dramatic story or photo shows what can happen to one person, not how likely it is. Look for numbers and study sizes.
- "Causes" is a high bar. A side effect showing up in reports doesn't mean the drug caused it. Regulators and researchers exist to sort correlation from cause, so check what they concluded.
- Look for the missing context. "You regain the weight" is true and misleading at the same time, depending on whether the chronic-disease framing is included.
- Ask who benefits. Sellers of miracle alternatives and outrage-driven feeds both have reasons to distort.
Study findings above are attributed to their authors and were located via PubMed.
This is general education, not medical advice. Whether a GLP-1 medication is right for you, and how to weigh its real risks and benefits, is a conversation for you and your prescriber or a qualified clinician who knows your history.